HK1222864A1 - Pcsk9的小分子调节剂和其使用方法 - Google Patents

Pcsk9的小分子调节剂和其使用方法 Download PDF

Info

Publication number
HK1222864A1
HK1222864A1 HK16110987.6A HK16110987A HK1222864A1 HK 1222864 A1 HK1222864 A1 HK 1222864A1 HK 16110987 A HK16110987 A HK 16110987A HK 1222864 A1 HK1222864 A1 HK 1222864A1
Authority
HK
Hong Kong
Prior art keywords
compound
substituted
amino
unsubstituted
alkyl
Prior art date
Application number
HK16110987.6A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼爾‧瓜伊
丹尼尔‧瓜伊
謝爾登‧克蘭
谢尔登‧克兰
尼古拉斯‧拉尚斯
讓-弗朗索瓦‧基亞森
让-弗朗索瓦‧基亚森
武伊‧靈‧長
武伊‧灵‧长
帕特里克‧拉孔貝
帕特里克‧拉孔贝
凱瑟琳‧斯科雷
凯瑟琳‧斯科雷
納比爾‧
纳比尔‧G‧赛义达
‧賽義達
Original Assignee
阿达拉塔合夥有限公司
埃莫化工控股有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿达拉塔合夥有限公司, 埃莫化工控股有限公司 filed Critical 阿达拉塔合夥有限公司
Publication of HK1222864A1 publication Critical patent/HK1222864A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Crystallography & Structural Chemistry (AREA)
HK16110987.6A 2013-03-15 2014-03-14 Pcsk9的小分子调节剂和其使用方法 HK1222864A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792249P 2013-03-15 2013-03-15
US61/792,249 2013-03-15
PCT/CA2014/050255 WO2014139008A1 (en) 2013-03-15 2014-03-14 Small molecule modulators of pcsk9 and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1222864A1 true HK1222864A1 (zh) 2017-07-14

Family

ID=51535727

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110987.6A HK1222864A1 (zh) 2013-03-15 2014-03-14 Pcsk9的小分子调节剂和其使用方法

Country Status (10)

Country Link
US (1) US20160031935A1 (enExample)
EP (1) EP2961765A4 (enExample)
JP (1) JP2016511274A (enExample)
KR (1) KR20150132362A (enExample)
CN (1) CN105431447A (enExample)
AU (1) AU2014231330A1 (enExample)
BR (1) BR112015023761A2 (enExample)
CA (1) CA2905237A1 (enExample)
HK (1) HK1222864A1 (enExample)
WO (1) WO2014139008A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
WO2016029037A1 (en) 2014-08-21 2016-02-25 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
US20170290806A1 (en) * 2014-09-08 2017-10-12 Temple University-Of The Commonwealth System Of Higher Education PCSK9 Inhibitors and Methods of Use Thereof
EP3973958A3 (en) * 2015-03-20 2022-06-22 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
HRP20220479T1 (hr) 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
AU2017281332A1 (en) 2016-06-24 2018-12-20 F. Hoffmann-La Roche Ag Compositions and methods for treating cardiovascular disease
GB2567210B (en) 2017-10-06 2020-01-15 Rolls Royce Plc A bladed disk
CN109096247A (zh) * 2018-08-15 2018-12-28 上海罕道医药科技有限公司 一种3h双吖丙啶基双取代吡啶衍生物的制备方法
CN119060040A (zh) 2019-01-18 2024-12-03 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
LV15544A (lv) * 2019-07-01 2021-01-20 Latvijas Organiskās Sintēzes Institūts Jauni borskābi saturoši peptidomimētiķi kā malārijas serīna proteāzes inhibitori
WO2024163598A2 (en) * 2023-01-31 2024-08-08 Brandeis University Peptides comprising thioester groups, including depsipeptide thioesters, methods of making, and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9712114A (pt) * 1996-09-24 1999-08-31 Procter & Gamble Composições detergente líquidas para lavanderia contendo enzima proteolítica e inibidores de protease.
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
JP2005531540A (ja) * 2002-04-30 2005-10-20 トラスティーズ・オブ・タフツ・カレッジ セリンプロテアーゼ阻害剤のスマートプロドラッグ
WO2008125623A2 (en) * 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
BR112012022060A2 (pt) * 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
MX357561B (es) * 2012-02-16 2018-07-13 Rqx Pharmaceuticals Inc Antibióticos peptídicos lineales.

Also Published As

Publication number Publication date
AU2014231330A1 (en) 2015-10-01
US20160031935A1 (en) 2016-02-04
CA2905237A1 (en) 2014-09-18
BR112015023761A2 (pt) 2017-07-18
WO2014139008A1 (en) 2014-09-18
JP2016511274A (ja) 2016-04-14
CN105431447A (zh) 2016-03-23
EP2961765A4 (en) 2016-11-09
EP2961765A1 (en) 2016-01-06
KR20150132362A (ko) 2015-11-25

Similar Documents

Publication Publication Date Title
HK1222864A1 (zh) Pcsk9的小分子调节剂和其使用方法
CN110809467B (zh) Sestrin-gator2相互作用的调节剂及其用途
AU2018205019C1 (en) Inhibitors of transglutaminases
CN110099907A (zh) 靶向蛋白质的噻吩并吡咯衍生物、组合物、方法及其用途
RU2652987C2 (ru) Производные пиридинона в качестве ингибиторов трансглутаминазы тканей
KR19980703151A (ko) 락탐-함유 히드록삼산 유도체, 그의 제조 그리고 매트릭스 메탈로프로테아제의 억제제로서의 그의 용도
BRPI0709610A2 (pt) compostos ligantes do domìnio iap bir
EP2310402A1 (en) Bridged secondary amines and use thereof as iap bir domain binding compounds
JP2020531440A (ja) 活性酸素種スカベンジャー誘導体の調製および使用
CN111356699A (zh) 活性氧清除剂的制备及用途
RS58235B1 (sr) Triazin jedinjenje i njegova upotreba u medicinske svrhe
JP2015051985A (ja) カテプシンｂの阻害剤
Bhattarai et al. LMP2 inhibitors as a potential treatment for Alzheimer’s disease
CN116670133A (zh) α 蛋白激酶1抑制剂及使用方法
EA021237B1 (ru) Производные бензамида и их применение в качестве ингибиторов hsp90
CN110214133A (zh) N-{[2-(哌啶-1-基)苯基](苯基)甲基}-2-(3-氧代-3,4-二氢-2H-1,4-苯并噁嗪-7-基)乙酰胺衍生物及相关化合物作为RORγ调节剂用于治疗自体免疫疾病
KR101244609B1 (ko) 트리펩티드 및 테트라펩티드 티오에테르
EP1080104B1 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
US20230064249A1 (en) Sirtuin 6 protein deacylase (sirt6) activators
TW201418198A (zh) 轉麩醯胺酸酶ｔｇ２抑制劑，醫藥組成物及其使用方法
US6689801B2 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
EP4058448A1 (en) Substituted hydantoinamides as adamts7 antagonists
Bhattarai et al. CNS-penetrant LMP2 Inhibitors as Potential Therapies for Age-related Macular Degeneration
CN119451944A (zh) Prep结合配体
HK40029856B (en) Preparation and uses of reactive oxygen species scavenger derivatives